Persistent orofacial pain (POFP) is common and caused by a group of conditions affecting the face, head, or mouth. Recent research highlighted a problematic care pathway with high costs to the health care provider, but the financial impact on patients and employers is not understood. This study aimed to describe patient (out-of-pocket) and employer (indirect) costs of POFP and to identify whether the dichotomized Graded Chronic Pain Scale (GCPS) was predictive of costs. A cohort of 198 patients was recruited from primary and secondary care settings in North East England and followed over a 24-mo period. Patients completed the GCPS and Use of Services and Productivity Questionnaire every 6 mo and a Time and Travel Questionnaire at 14 mo. Questionnaires examined the implications of health care utilization on patients' everyday lives and personal finances. Time and travel costs were calculated and applied to use-ofservices data to estimate out-of-pocket costs, while the human capital method and QQ method (quantity and quality of work completed) were used to estimate absenteeism and presenteeism costs, respectively. Per person per 6-mo period (in 2017 pounds sterling), mean out-of-pocket costs were £333 (95% CI, £289 to £377), and indirect costs were £1,242 (95% CI, £1,014 to £1,470). Regression analyses indicated that over 6 mo, the GCPS was predictive of the following: out-of-pocket costs-a difference of £311 between low and high GCPS per person per 6-mo period (95% CI, £280 to £342; P < 0.01, n = 705 observations over 24 mo); indirect costs-a difference of £2,312 between low and high GCPS per person per 6-mo period (95% CI, £1,886 to £2,737; P < 0.01; n = 352 observations over 24 mo). This analysis highlights "hidden" costs of POFP and supports the use of the dichotomized GCPS to identify patients at risk of higher impact and associated costs and thereby stratify care pathways and occupational health support appropriately.
Introduction
Persistent orofacial pain (POFP) refers to a group of conditions affecting the face and mouth and includes temporomandibular disorders, burning mouth syndrome, persistent dentoalveolar pain, trigeminal neuralgia, and atypical facial pain (persistent idiopathic facial pain). Prevalence rates of 5% to 14% have been reported (Macfarlane et al. 2001; Aggarwal et al. 2010; Horst et al. 2015; Goulet and Woda 2017) , and these figures suggest that POFP is relatively common.
Recent qualitative data from individuals experiencing POFP indicate problems with the existing care pathway (Breckons et al. 2017 ). This research describes how patients attend a large number of appointments with different health care professionals but fail to obtain effective diagnoses, treatment, or referral for their pain. Research highlighting health care providers' perspectives on POFP corroborates these findings as it suggests difficulties diagnosing and treating POFP (Durham et al. 2007; Aggarwal, Joughin, Zakrzewska, Appelbe, and Tickle 2011; Aggarwal, Joughin, Zakrzewska, Crawford, and Tickle 2011; Peters et al. 2015) in addition to service constraints, including limited numbers of specialist services (Aggarwal, Joughin, Zakrzewska, Appelbe, and Tickle 2011) . Collectively, these studies suggest a problematic care pathway from provider and patient perspectives.
Recent data outlined costs associated with POFP from a health service provider's perspective and suggested that painrelated disability, as measured by the dichotomized Graded Chronic Pain Scale (GCPS; Von Korff et al. 1992) , is predictive of direct health service costs and thereby a proxy of treatment need (Durham et al. 2016) . These data also suggested that health service costs are primarily driven by a high number of consultations.
While research is limited, there is some suggestion that for pain conditions similar to POFP, such as headache, a large proportion of costs are associated with reduced productivity at work-so-called presenteeism (Linde et al. 2012) . This is in 773310J DRXXX10.1177/0022034518773310Journal of Dental ResearchDEEP Study contrast to a persistent pain condition, such as lower back pain, for which indirect costs may be composed of a larger proportion of absence-related costs-that is, absenteeism (Juniper et al. 2009 ). To our knowledge, no research has examined costs of POFP from the perspective of patients or employers, which are important from a health policy perspective to understand the potential implications to the wider economy. The aim of this study was therefore to describe the indirect and out-ofpocket costs of POFP and determine whether dichotomized GCPS status is predictive of either of these.
Methods
Ethical approval for the study was obtained via the local research ethics committee (National Research Ethics Service reference 12/YH/0338). The full protocol of the study is available in open access format (Durham et al. 2014) .
Sample and Recruitment
A sample size calculation indicated that 200 participants were needed (α = 0.05) to detect a moderate effect size of 0.4 (Cohen 1988 ) between groups with 2-tailed inferential statistics with 80% power. This sample size also allowed us to examine up to 30 predictors of costs with regression analyses at a moderate effect size (α = 0.05, β = 0.8; Green 1991). The dichotomized GCPS was the predictor of interest, given that it demonstrated prognostic value (Von Korff et al. 1992) and was shown to be predictive of health service costs in POFP (Durham et al. 2016) . Participants were recruited from primary care (community) dental practices (n = 10) and medical practices (n = 25) and secondary care (hospital/specialist) from a range of departments (neurology, oral medicine, oral and maxillofacial surgery, and restorative dentistry) in North East England, as well as through self-referral via health care and public advertisements. People were eligible for this study if they:
• • had experienced orofacial pain for ≥3 mo;
• • screened positive with validated self-report screening instruments for musculoskeletal, neuropathic, or vascular origin of pain; • • were ≥18 y old; and • • were able to provide informed consent and communicate complex constructs in English.
The recruitment strategy was to recruit 240 patients to allow for an anticipated 20% attrition rate over the 2-y follow-up. Recruiting clinicians returned a pro forma, upon receipt of which the study team contacted patients by telephone to conduct a standardized validated screening questionnaire. This screening tool (Hapak et al. 1994; Gonzalez et al. 2011) classified the origin of patients' pain into 1) musculoskeletal, 2) neuropathic/vascular, or 3) combined. This screening method's sensitivity and specificity were previously reported for this study (Durham et al. 2016) : musculoskeletal (sensitivity, 63.1%; specificity, 85.9%) and neuropathic/vascular (sensitivity, 66.3%; specificity, 96.8%). Upon positive screening, patients were invited to participate in the study, and the study team obtained written informed consent. Patients who screened negative were thanked for their time and did not take part in the study unless a specialist clinical diagnosis was available indicating that the screening result was a false negative.
Data Collection
Four instruments were used to collect patient data for the present analysis.
Case Report Form. Upon entry into the study, all participants completed a structured telephone interview with a trained interviewer in which they reported the following: demographic and socioeconomic details (education level, employment status, income, residential area), the details of their health care contacts, and the treatments received over the duration of their pain up to that point in time. Residential area was used to allocate an Index of Multiple Deprivation (the official measure of deprivation in England; Department for Communities and Local Government 2015).
Use of Services and Productivity Questionnaire. The Use of Services and Productivity Questionnaire (USPQ; Thompson and Wordsworth 2001 ) was completed at baseline and 6, 12, 18, and 24 mo. This is a 2-part questionnaire. Part 1 collects data on use of health services over the past 6 mo: participants were asked to report how many times they had visited different types of health care professionals (from a list provided) and any outof-pocket expenditure on over-the-counter medication, prescription charges, NHS (National Health Service) dental treatment, or private treatment and any additional costs attributable to POFP. Part 2 collects data on participants' employment status, number of days contracted, and the number of days in the previous 6 mo that individuals were absent from ("absenteeism") or attended ("presenteeism") work with pain. The quality and quantity method (QQ method; Brouwer et al. 1999) and Work Attendance with Health Problems Scale from the Health and Labour Questionnaire (Van Roijen et al. 1996) were incorporated into the USPQ (Appendix Fig. 1 ).
For the QQ method, participants were asked to indicate on 2 numeric rating scales the quality and quantity of work performed while working with pain (1, practically nothing / very poor quality; 10, normal quantity / normal quality). The Work Attendance with Health Problems Scale is based on a list of 6 problems with a 4-point ordinal-scale response indicating frequency (Appendix Fig. 3 ).
Time and Travel Questionnaire. The Time and Travel Questionnaire (Thompson and Wordsworth 2001) was completed at 14 mo: Participants were asked to report-for all the health care professionals whom they had visited-the distance, duration, and usual mode of transport to appointments and to provide additional information, such as whether they were accompanied by someone or required child care. Participants were also asked what their activity would have been if they had not been attending a health care professional (Appendix Fig. 2 ).
Graded Chronic Pain Scale. The GCPS (Von Korff et al. 1992 ) was used to assess pain-related disability at 0, 6, 12, 18, and 24 mo. Its summary score allows classification on a 5-point ordinal scale from grade 0 (low intensity, low disability) to grade 4 (high disability, severely limiting). A dichotomized GCPS score (high, 4-2b; low, 2a-0) was then calculated from the 5-point ordinal scale with an algorithm developed by Dworkin et al. (2002) .
Data Analysis
Prior to data analysis, data were cross-checked by 2 researchers (M.B. and J.D.) and cleaned to remove errors, inconsistencies, or unfeasible responses. Costs collected over the 2-y study period were all converted into 2012 prices (the year the study started) within the analysis and adjusted for inflation with the Consumer Price Index, a measure of change in prices of goods and services over time from the Office for National Statistics (procedure described in detail in Appendix Fig. 4 ). The resulting final costs were then converted to the latest price year with the most recent Consumer Price Index figure available and are presented in 2017 pounds sterling (average UK exchange rate for 2017: UK £1.00 = US $1.28). Costs were calculated by time point, and then all cost data were pooled from all time points, thereby allowing calculation of a mean cost per 6-mo period over the entire study. Discounting of costs was not required, as we were examining average costs for a 6-mo period only.
Patient Out-of-pocket Costs. Out-of-pocket costs were the sum of the following 3 categories.
Treatment and assessment costs. Treatment and assessment costs related to fees that individuals had to pay directly: prescription charges, NHS dental costs, private treatment costs, and over-the-counter medication. Participants reported these costs directly at each time point in the USPQ, and values reported are the sum of the reported costs.
Time and travel costs. Time and travel costs consisted of travel costs to and from appointments (e.g., public transport, private vehicle, or taxi costs) and travel and appointment time costs (e.g., lost wages or leisure time). Data from the Time and Travel Questionnaire were used to calculate a unit cost per type of appointment for each patient (Appendix Fig. 5 ). Hourly and daily wages were calculated with annual salary information (from the case report form) and days worked per week (from the USPQ). Standard UK values were used for mileage rates and leisure time (Appendix Fig. 6 ; Douglas and Johnson 2004 ). This unit cost was then applied to the number of appointments reported at each time point in the USPQ. Companion costs (where reported) were calculated identically and added to the participant costs.
Additional costs. Additional costs consisted of any additional reported expenditure that patients attributed to their POFP.
Indirect Costs. For the subsample of participants who reported being employed, we estimated the cost of the absenteeism to the employer using the human capital method (Van den Hout 2010), which applies a participant's daily wage to the length of time they reported being absent. Costs related to presenteeism were calculated with the QQ method (Brouwer et al. 1999) , the details of which are provided in Appendix Figure 7 .
Statistical Procedures. All analyses were performed with STATA 13 (StataCorp LP). Descriptive statistics were calculated to describe mean and SD values of costs. Parametric inferential statistical tests were used to examine the possible time effect on costs. Bootstrapping (bias-corrected accelerated method with 1,000 repetitions) was used to produce confidence intervals around mean values. As appropriate for cost data with a skewed distribution (Barber and Thompson 2004) , generalized linear models (GLMs) with a log-link function were used to examine the relationship between dichotomized GCPS status and out-of-pocket costs and indirect costs, controlling for demographic and socioeconomic factors, including age, sex, education level (no public examinations, secondary examinations, degree or higher), index of multiple deprivation (50% least deprived, 50% most deprived), and duration of pain at start of the study (<1 y, 1 to 4 y, ≥5 y). Time point dummy variables were also included in the regression to control for any possible time effect.
The size of the sample varied by time point, and dropout/ nonresponse is described in detail in the Figure. Participants were included in this analysis if they returned the USPQ and GCPS. Missing data rates for respondents were low; across the time points, the mean level of missing data was between 2% and 6%. Missing data were imputed with UK reference costs and/or mean/median imputation where appropriate (for details and examples, see Appendix Fig. 8 ). This report follows the Strengthening the Reporting of Observational Studies in. Epidemiology (STROBE) guidelines for reporting cohort studies (Von Elm et al. 2014 ) and the relevant points of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist (Husereau et al. 2013) .
Results
For the overall study, 387 individuals were referred for screening, and 279 agreed to be screened. Of those, 268 screened positive and met inclusion criteria, and 239 of these individuals agreed to participate (for details of recruitment location, see Appendix Table 1 ). The Consolidated Standards of Reporting Trials (CONSORT) diagram (Fig.) demonstrates the flow of participants through the study. For this article, patients were included in the analysis at a time point if they had GCPS and USPQ data. Table 1 demonstrates the sociodemographic details of the sample included in the analysis at each time point. The changing number of individuals at each time point represents those who dropped out, most frequently by nonresponse. Within a 6-mo period, the cohort reported a mean of 9 (SD, 12) health care appointments. Table 2 demonstrates total out-of-pocket costs per person per 6-mo period for these visits, as well as treatment and assessment costs incurred due to POFP (mean, £333; 95% CI, £289 to £377).
Out-of-pocket Costs
The total number of observations in the GLM regression (Appendix Table 2 ) was 705 over the 5 time points due to missing sociodemographic data. The regression indicated that those with a high GCPS (n = 227) had increased out-of-pocket costs. Specifically, those with a low GCPS (n = 478) had mean outof-pocket costs of £240 (95% CI, £230 to £250), as opposed to £551 (95% CI, £522 to £581) for those with a high GCPS ( Table 3) . The difference in cost between groups was a mean of £311 (95% CI, £280 to £342; P < 0.01) per person per 6-mo period. While out-of-pocket costs did not differ significantly between months 0 and 6, out-of-pocket costs were significantly less than baseline at months 12, 18, and 24, F(4, 785) = 4.90 (P < 0.01; Appendix Fig. 9 ).
Indirect Costs
At each time point, around half of the participants (range, 48.5% to 51.7%; Appendix Table 3 ) reported being employed. Those employed reported missing a mean 1.7 d (SD, 5.9) over a 6-mo period due to their POFP. This absenteeism equated to an employer cost of £174 (95% CI, £113 to £236) per person per 6-mo period (Table 4) . Those employed reported attending work with pain for a mean 34.6 d (SD, 42.9) per 6-mo period. The QQ method suggested a mean decrease of 17.4% (SD, 20.7%) over the 24 mo of observations in the quantity of work completed while in pain (mean, 8.3 of 10; SD, 2.1) and 16.9% (SD, 18.8%) in the quality (8.3 of 10; SD, 1.9). These reported losses were used to estimate mean employer costs of £1,068 (95% CI, £849 to £1,287) per person per 6-mo period due to presenteeism. The most commonly reported problem facing individuals while at work was "problems concentrating" (73%) due to POFP, followed by "decision making" (59%; Appendix  Fig. 3) .
The total number of observations in the GLM regression over the 5 time points (Appendix Table 4 ) was 352 due to missing sociodemographic data. The regression demonstrated that those with a high GCPS status (n = 101) had higher indirect costs. Specifically, those with a low GCPS (n = 251) had mean indirect costs of £681 (95% CI, £631 to £730), as opposed to £2,992 279 screened for eligibility 239 recruited at baseline Figure. CONSORT diagram showing patient flow over the 2-y followup period. 1 There was no significant difference in age, gender or origin of pain between positively screened patients who participated and those who declined (P > 0.05). 2 There were no significant differences in gender, ethnicity, duration of pain or origin of pain between those dropping out and the 198 participants whose data was included in the study (P > 0.05). However those participating were significantly older than those who dropped out (P < 0.01). 3 One patient withdrew from the study at M18 and requested that their data be withdrawn. 4 Data was not received from 3 participants at M0 who reported returning data but this was not received by the study team. These patients returned data at subsequent time points. 5 There was no significant difference between those dropping out at M6 and the M0 sample on the basis of: age, gender, ethnicity, duration of pain or origin of pain (P > 0.05). 6 There was no significant difference between those dropping out at M12 and the M0 sample on the basis of: age, gender, ethnicity or origin of pain (P > 0.05) although those dropping out had a significantly longer duration of pain to those participating at baseline (P < 0.05). 7 One of these patients went on to complete data at a further time point. 8 There was no significant difference between those dropping out at M14 and the M0 sample on the basis of: age, gender, ethnicity, duration of pain or origin of pain (P > 0.05). 9 Three of these patients went on to return data at subsequent time points. 10 There was no significant difference between those dropping out at M18 and the M0 sample on the basis of: age, gender, duration of pain or origin of pain (P > 0.05), although those dropping out consisted of a greater proportion of a White British ethnic group than those participating at baseline (P < 0.01). 11 There was no significant difference between those dropping out at M24 and the M0 sample on the basis of: age, gender, duration of pain or origin of pain (P > 0.05), although those dropping out consisted of a greater proportion of a White British ethnic group than those participating at baseline (P < 0.01).
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(95% CI, £2,575 to £3,410) for those in the high GCPS. The difference in costs between the groups was £2,312 (95% CI, £1,886 to £2,737; P < 0.01) per person per 6-mo period. Although the employer costs did not differ significantly over the first 4 time points (Appendix Fig. 10 ), month 24 patient costs were significantly less than month 6 costs, F(4, 390) = 3.42 (P < 0.01).
Discussion
This analysis builds on work examining costs of POFP (Durham et al. 2016 ) and suggests that, in addition to health service costs, there are considerable out-of-pocket and indirect costs to be considered that fall on patients and their families and employers. Research in other conditions has highlighted the burden on the individual caused by financial demands of a chronic condition (Piette et al. 2004 ). Additionally, our data highlight a need to ensure that presenteeism is assessed, as absenteeism taken in isolation may underestimate the impact of persistent pain conditions on the workforce.
These data suggest that the GCPS may have predictive value in identifying those who are likely to incur high out-ofpocket and indirect costs and thus be at risk of the impact of these additional costs. This analysis also suggests that in addition to the potential of the dichotomized GCPS to predict higher health care costs, it may be a useful screening tool for determining who is at risk of incurring the highest out-ofpocket costs and having their work affected by their pain. The most common problems affecting individuals while working with POFP were difficulties concentrating and making decisions alongside having to work at a slower pace. The GCPS represents a way to screen those who are in the greatest need of occupational health support while continuing ongoing management for their POFP. It may be possible then, as in similar pain conditions (e.g., migraine), to institute simple logistical, educational, or pacing interventions that will help improve the quality of work and work environment for those experiencing POFP, thereby improving productivity and reducing the effect of presenteeism (Vicente-Herrero et al. 2004; Berry 2007; McLean 2009; Parker and Waltman 2012) . There are, however, no data currently available on what measures would be sensible to help those experiencing POFP while at work, and this is an area for further research.
Our previous quantitative and qualitative research (Durham et al. 2016; Breckons et al. 2017) highlighted the large number of appointments that individuals attend in an attempt to obtain a diagnosis and treatment for their POFP. This difficult and convoluted care pathway increases the distress to the patient and the cost to the health service. Data from the current study also demonstrate its wider economic impact. Durham et al. (2016) suggested that a stratified system may offer advantages over the current system, and this study provides support for the idea of such a pathway.
There are several limitations to this study: with regard to the size and selection of the cohort, we recruited from a single region of the United Kingdom; therefore, we do not know how generalizable our results are. Additionally, we recruited people who had experienced POFP for varying lengths of time: given that the data suggest a possible temporal downward trend in out-of-pocket and indirect costs, it would be of further interest to investigate costs beyond the duration of the study to provide a clearer picture of longer-term implications to patients and employers. While the level of missing data was generally low, as with all treatment of missing data, imputation and assumptions of questions being nonapplicable have the potential to under-or overestimate costs. In addition, study dropout always has the potential to introduce selection bias.
In summary, POFP is known to have a profound and debilitating impact on people's lives, and this article highlights "hidden" costs of the condition. Future work should focus on how care pathways can be designed to better meet the needs of patients. Given the high levels of presenteeism and the potential financial impact on employers, further research is warranted on how people experiencing POFP can be supported at work.
Author Contributions
M. Breckons, contributed to data acquisition, analysis, and interpretation, drafted and critically revised the manuscript; J. Shen, contributed to data analysis and interpretation, drafted and critically revised the manuscript; J. Bunga, contributed to data analysis and interpretation, critically revised manuscript; L. Vale, contributed to conception, design, data analysis, and interpretation, critically revised manuscript; J. Durham, contributed to conception, design, data acquisition, analysis, and interpretation, drafted and critically revised manuscript. All authors gave final approval and agree to be accountable for all aspects of the work.
